Aceso Life Science Group Limited (HKG:0474)
Hong Kong · Delayed Price · Currency is HKD 0.1500
+0.0040 (2.74%)
Aug 21, 2026, 4:08 PM HKT
Aceso Life Science Group Balance Sheet
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 126 | 132 | 350 | 187 | 195 |
Long-Term Investments | 269 | 1,093 | 1,245 | 1,933 | 1,829 |
Trading Asset Securities | 200 | 80 | 119 | 415 | 522 |
Loans & Lease Receivables | 26 | 87 | 549 | 654 | 824 |
Other Receivables | 56 | 198 | 213 | 132 | 259 |
Property, Plant & Equipment | 8 | 191 | 253 | 281 | 283 |
Other Intangible Assets | - | 4 | 171 | 171 | 158 |
Other Current Assets | 19 | 32 | 32 | 597 | 110 |
Long-Term Deferred Tax Assets | 8 | 7 | 58 | 54 | 53 |
Other Long-Term Assets | 1,076 | 1,417 | 1,794 | 1,875 | 1,656 |
Total Assets | 1,788 | 3,243 | 4,786 | 6,301 | 6,263 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 1 | 4 | 6 | 13 | 6 |
Accrued Expenses | - | 91 | 57 | 62 | 108 |
Current Portion of Long-Term Debt | 60 | 1,714 | 2,053 | 2,137 | 2,124 |
Current Portion of Leases | 3 | 11 | 10 | 14 | 12 |
Long-Term Debt | 1,144 | 561 | 666 | 756 | 857 |
Long-Term Leases | 1 | 15 | 9 | 15 | 17 |
Current Income Taxes Payable | 2 | 19 | 16 | 25 | 20 |
Other Current Liabilities | 121 | 66 | 70 | 600 | 179 |
Long-Term Deferred Tax Liabilities | 2 | 17 | 84 | 100 | 111 |
Total Liabilities | 1,334 | 2,499 | 2,973 | 3,726 | 3,436 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 88 | 73 | 73 | 73 | 74 |
Additional Paid-In Capital | - | 4,811 | 4,811 | 4,811 | 4,811 |
Retained Earnings | - | -4,338 | -3,443 | -2,981 | -2,717 |
Comprehensive Income & Other | 369 | -508 | -507 | -341 | -161 |
Total Common Equity | 457 | 12 | 921 | 1,549 | 2,002 |
Minority Interest | -3 | 732 | 892 | 1,026 | 825 |
Shareholders' Equity | 454 | 744 | 1,813 | 2,575 | 2,827 |
Total Liabilities & Equity | 1,788 | 3,243 | 4,786 | 6,301 | 6,263 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 1,208 | 2,301 | 2,738 | 2,922 | 3,010 |
Net Cash (Debt) | -882 | -2,089 | -2,269 | -2,320 | -2,293 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.12 | -0.29 | -0.31 | -0.32 | -0.31 |
Filing Date Shares Outstanding | 8,858 | 7,382 | 7,382 | 7,382 | 7,387 |
Total Common Shares Outstanding | 8,858 | 7,382 | 7,382 | 7,382 | 7,387 |
Working Capital | 240 | -1,375 | -949 | -868 | -167 |
Book Value Per Share | 0.05 | 0.00 | 0.12 | 0.21 | 0.27 |
Tangible Book Value | 457 | 8 | 750 | 1,378 | 1,844 |
Tangible Book Value Per Share | 0.05 | 0.00 | 0.10 | 0.19 | 0.25 |